Latest Diabetes mellitus type 1 Stories

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has named Richard A. Franco, Sr. to its Board of Directors. Richard A. Franco is the President of the Richard's Group, Ltd., a healthcare advisory firm and cofounder of LipoScience, Inc. He has over 35...

Connie K. Ho for redOrbit.com – Your Universe Online Fatigue. Hunger. Weight loss. These are just a few of the symptoms related to diabetes. With the diagnosis of the disease, it can sometimes be difficult for patients to manage. However, researchers from the Mayo Clinic recently discovered that, after removal of the entire pancreas, patients can better control their diabetes. Before the procedure, these patients were identified as having cancer or precancerous cysts in the pancreas....

Researcher finds autoimmune response contributes to inflammation in the artery wall Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system. A number of research studies have demonstrated inflammation's role in fueling plaque buildup, also...

Connie K. Ho for redOrbit.com – Your Universe Online Researchers recently discovered that a tuberculosis vaccine could decrease autoimmunity and boost insulin production in patients who have long-term Type 1 diabetes. The vaccine has been utilized for the past 90 years and scientists believe that it could help eliminate the necessity of having insulin injections for patients with Type 1 diabetes. With Type 1 diabetes, patients normally need to inject insulin on a daily basis so...

Treatment with generic vaccine kills autoimmune cells, temporarily restoring insulin production A phase I clinical trial has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes. Results of the study – led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital...

UCSF study suggests stress-amplifying 'TXNIP' protein may be powerful new drug target At its most fundamental level, diabetes is a disease characterized by stress -- microscopic stress that causes inflammation and the loss of insulin production in the pancreas, and system-wide stress due to the loss of that blood-sugar-regulating hormone. Now, researchers led by scientists at the University of California, San Francisco (UCSF) have uncovered a new key player in amplifying this stress in...

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has signed a strategic alliance with Spring Point Project. Spring Point Project's team has unique experience under the current Good Manufacturing Practices (cGMP) required by U.S. Food and Drug Administration...

LANSING, Mich., Aug. 2, 2012 /PRNewswire/ -- Accident Fund Holdings, Inc. is proud to announce it has raised more than $50,000 to benefit the Juvenile Diabetes Research Foundation (JDRF) through a variety of efforts by its employees, exceeding its fundraising goal by $5,000. (Logo: http://photos.prnewswire.com/prnh/20100727/DE40865LOGO ) Since its inception in 1970, JDRF has provided more than $1.6 billion for diabetes research. Each year, more than 15,000 children are diagnosed...

HILLIARD, Ohio, Aug. 1, 2012 /PRNewswire/ -- e-Cycle, the first mobile buyback and recycling company to receive the stringent e-Stewards certification, will partner with Ford Motor Company this August on a month-long initiative to raise funds for type 1 diabetes (T1D) research while recycling wireless phones. "We look forward to working with e-Cycle and JDRF on this important initiative to raise funds for diabetes research," said Robert Brown, vice president, Sustainability,...

SAN ANTONIO, July 30, 2012 /PRNewswire/ -- (OTCQB: BISU) (PINKSHEETS: BISU) Bio-Solutions Corp is pleased to announce that the company has started production of the recently acquired Type2 Defense(TM). Type2 Defense(TM) is an Antioxidant and glucose control dietary supplement powder. This proprietary formula is packaged with 30 packets to a box. The product powder drink mix delivery system has been developed to support healthy glucose levels for type 2 diabetics and pre-diabetics....